Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Thursday, September 24, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Acadia Pharmaceuticals has reported positive topline results from the Phase 2 segment of the RADIANT study, which evaluates remlifanserin for treating hallucinations and delusions in Alzheimer's disease psychosis. The primary endpoint, assessing changes in symptoms, indicates a favorable outcome for the 60 mg dosage. This sets the stage for further Phase 3 trials.
Market Sentiment Analysis
POSITIVE FACTORS
Phase 3 enabling topline results are promising.
Remlifanserin shows potential for treating ADP symptoms.
The study is part of a larger ongoing clinical trial program.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
4.5%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanse
Frequently Asked Questions
What are the topline results from the RADIANT study?
The topline results indicate positive outcomes for remlifanserin in treating Alzheimer's disease psychosis.
What is the primary endpoint of the RADIANT study?
The primary endpoint assesses changes in hallucinations and delusions using the SAPS-H+D scale.
What dosage of remlifanserin was evaluated?
The study evaluated a once-daily dosage of 60 mg of remlifanserin.
What is the significance of these results?
These results enable the progression to Phase 3 trials, indicating potential for effective treatment.